We are a development stage biotechnology company working on a new way of treating cancer – cell therapy – that uses the patient’s own immune cells to attack the tumor. This personalized approach is based on using genomics to analyze the patient’s tumor and identify mutations that can be targeted with Adoptive Cell Therapy. Our proprietary platforms identify neoantigens and select T-cells with receptors that can recognize the neoantigens and fight the tumor.